Literature DB >> 31309419

A case of central nervous system graft-versus-host disease following allogeneic stem cell transplantation.

Gi-June Min1, Silvia Park1, Sung-Soo Park1, Jae-Ho Yoon1, Sung-Eun Lee1, Byung-Sik Cho1,2, Ki-Seong Eom1,2, Seok Lee1,2, Hee-Je Kim1,2, Chang-Ki Min1,2, Seok-Goo Cho1, Dong-Wook Kim1,2, Jong-Wook Lee1, Yoo-Jin Kim3,4.   

Abstract

Graft-versus-host disease (GVHD) is a serious complication of allogeneic stem cell transplantation (SCT). Here, we report a rare case of GVHD involving the central nervous system (CNS). A 35-year-old woman was diagnosed with myelodysplastic syndrome unclassifiable and underwent allogeneic peripheral blood SCT for disease progression to myelodysplastic syndrome with excess blasts-2. One year following SCT, she experienced chronic oral and hepatic GVHD symptoms, which were managed with oral steroids and tacrolimus. Sixteen months after SCT, she developed sudden-onset, generalized, tonic-clonic-type seizures. Magnetic resonance imaging and cerebrospinal fluid evaluation showed multiple discrete white lesions and elevated IgG levels. Brain biopsy revealed periventricular plaques with the destruction of axons, representing a demyelinating disease of the CNS. We diagnosed the case as CNS GVHD. Neurologic symptoms gradually improved with methylprednisolone pulse therapy and total plasma exchange combined with a calcineurin inhibitor; the brain lesions nearly disappeared after decreasing steroid maintenance dosage, and were completely resolved 1 year after the onset of CNS GVHD. The patient is CNS GVHD-symptom-free, 3-year post-transplantation. Thus, CNS GVHD should be considered in cases of newly developed neurologic symptoms in SCT recipients showing evidence of preceding chronic GVHD.

Entities:  

Keywords:  Allogeneic stem cell transplantation; Central nervous system graft-versus-host disease; Demyelination

Mesh:

Substances:

Year:  2019        PMID: 31309419     DOI: 10.1007/s12185-019-02702-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

1.  Central nervous system graft-versus-host disease post allogeneic stem cell transplant.

Authors:  Jake Shortt; Elspeth Hutton; Mark Faragher; Andrew Spencer
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

2.  Chronic demyelinating polyneuropathy in graft-versus-host disease following allogeneic bone marrow transplantation.

Authors:  Toshiko Nagashima; Fumie Sato; Takayo Chuma; Yukio Mano; Isao Sasaki; Masamitsu Mori; Toshio Higa; Nobuo Masauji; Masaharu Kasai; Yasuko Orba; Toshiya Shinohara; Kazuo Nagashima
Journal:  Neuropathology       Date:  2002-03       Impact factor: 1.906

3.  Cerebral vasculitis in graft-versus-host disease: a case report.

Authors:  John N Campbell; P Pearse Morris
Journal:  AJNR Am J Neuroradiol       Date:  2005-03       Impact factor: 3.825

4.  The central nervous system is a target of acute graft versus host disease in mice.

Authors:  Steffen Hartrampf; Jarrod A Dudakov; Linda K Johnson; Odette M Smith; Jennifer Tsai; Natalie V Singer; Mallory L West; Alan M Hanash; Michael H Albert; Bingfang Liu; Miklos Toth; Marcel R M van den Brink
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

5.  Angiitis of the central nervous system after allogeneic bone marrow transplantation?

Authors:  C S Padovan; K Bise; J Hahn; P Sostak; E Holler; H J Kolb; A Straube
Journal:  Stroke       Date:  1999-08       Impact factor: 7.914

6.  Central and peripheral nervous system complications following allogeneic bone marrow transplantation.

Authors:  C Solaro; A Murialdo; D Giunti; G Mancardi; A Uccelli
Journal:  Eur J Neurol       Date:  2001-01       Impact factor: 6.089

Review 7.  The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.

Authors:  Dimitrios Karussis
Journal:  J Autoimmun       Date:  2014-02-10       Impact factor: 7.094

8.  Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance.

Authors:  Deborah Siegal; Anne Keller; Wei Xu; Sandeep Bhuta; Dong Hwan Kim; John Kuruvilla; Jeffrey H Lipton; Hans Messner; Vikas Gupta
Journal:  Biol Blood Marrow Transplant       Date:  2007-09-21       Impact factor: 5.742

9.  Encephalomyelitis mimicking multiple sclerosis associated with chronic graft-versus-host disease after allogeneic bone marrow transplantation.

Authors:  Yayoi Matsuo; Kenjiro Kamezaki; Shoichiro Takeishi; Katsuto Takenaka; Tetsuya Eto; Atsushi Nonami; Toshihiro Miyamoto; Hiromi Iwasaki; Naoki Harada; Koji Nagafuji; Takanori Teshima; Koichi Akashi
Journal:  Intern Med       Date:  2009-08-17       Impact factor: 1.271

10.  Immune-mediated myelopathy after allogeneic marrow transplantation.

Authors:  H Openshaw; N E Slatkin; P M Parker; S J Forman
Journal:  Bone Marrow Transplant       Date:  1995-04       Impact factor: 5.483

View more
  3 in total

1.  A Case of Multiple Sclerosis-Like Relapsing Remitting Encephalomyelitis Following Allogeneic Hematopoietic Stem Cell Transplantation and a Review of the Published Literature.

Authors:  Joyutpal Das; Atta Gill; Christine Lo; Natalie Chan-Lam; Siân Price; Stephen B Wharton; Helen Jessop; Basil Sharrack; John A Snowden
Journal:  Front Immunol       Date:  2020-05-05       Impact factor: 7.561

2.  Noninvasive tools based on immune biomarkers for the diagnosis of central nervous system graft-vs-host disease: Two case reports and a review of the literature.

Authors:  Hai-Rong Lyu; Xiao-Yuan He; Hong-Jun Hao; Wen-Yi Lu; Xin Jin; Yu-Jiao Zhao; Ming-Feng Zhao
Journal:  World J Clin Cases       Date:  2021-02-26       Impact factor: 1.337

Review 3.  Central Nervous System-related Graft-versus-host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Yuta Kaito; Shunsuke Yui; Kazuki Inai; Daishi Onai; Ryosuke Kinoshita; Satoshi Yamanaka; Muneo Okamoto; Ryuichi Wada; Ryuji Ohashi; Koiti Inokuchi; Hiroki Yamaguchi
Journal:  Intern Med       Date:  2021-10-15       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.